ADC Therapeutics SA Reports Promising DLBCL Trial Results and Strategic Advancements
- ADC Therapeutics reports a 94% overall response rate in the LOTIS-7 trial for DLBCL using ZYNLONTA® and glofitamab.
- Patient enrollment is complete for the LOTIS-5 trial, evaluating ZYNLONTA® with rituximab in DLBCL patients.
- CEO Ameet Mallik highlights ADC Therapeutics' strong financial position and ongoing commitment to oncology research and development.
ADC Therapeutics Advances in Clinical Trials for DLBCL Treatment
ADC Therapeutics SA (NYSE: ADCT) makes significant strides in the field of oncology with promising updates from its clinical trials, particularly regarding its novel antibody-drug conjugate, ZYNLONTA®. In the recent LOTIS-7 Phase 1b trial, the combination of ZYNLONTA® and glofitamab demonstrates an impressive efficacy profile, reporting a 94% overall response rate (ORR) and a 72% complete response (CR) rate among patients suffering from relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Such strong initial data not only reflects the potential of this combination therapy but also positions ADC Therapeutics at the forefront of innovative treatments for a disease known for its challenging prognosis. Updates on these results are anticipated in the second quarter of 2025, further fueling optimism among stakeholders.
In addition to the LOTIS-7 trial, ADC Therapeutics successfully completes patient enrollment in the LOTIS-5 Phase 3 confirmatory trial. This pivotal study evaluates the efficacy of ZYNLONTA® in combination with rituximab for patients with DLBCL who have received at least two prior lines of therapy. With data expected to be released in late 2025, the trial holds significant importance for validating the therapeutic benefits of ZYNLONTA® and could potentially reshape treatment paradigms for DLBCL patients. The completion of enrollment is a critical milestone that underscores the company’s commitment to accelerating research and development in the oncology space.
CEO Ameet Mallik expresses confidence in ADC Therapeutics' trajectory, noting substantial achievements throughout 2024, including advancements in expansion trials and enhancements to their solid tumor program. The company’s financial stability is also evident, with a reported cash balance of $250.9 million as of December 31, 2024, ensuring operational continuity into the latter half of 2026. This robust financial position, combined with a strategic focus on reducing operational expenditures, reinforces ADC Therapeutics' capacity to pursue its ambitious goals as it approaches pivotal milestones in the upcoming year.
In addition to its clinical advancements, ADC Therapeutics plans to host a conference call on March 27, 2025, at 8:30 a.m. EDT to delve into these developments and provide further insights into the company’s strategies moving forward. This event is expected to attract attention from investors and industry professionals keen on understanding the implications of the latest trial results and the overall direction of the company. As ADC Therapeutics continues to navigate the complexities of cancer treatment, its innovative approaches and strong financial foundation position it well to address the urgent needs of patients battling DLBCL.